Tag: Drug development

Managing Excipient Incompatibility Issues During IND/NDA Submissions Excipient incompatibility identified late during IND/NDA filing can pose significant risks to the successful registration and market launch of pharmaceutical products. These challenges…

Strategic Playbook for Managing Bioavailability Risks During Tech Transfer Managing bioavailability risk during tech transfer is a critical aspect of pharmaceutical development that requires comprehensive assessment and mitigation strategies. As…

Tackling Scalability Challenges in Early Development: Regulatory Insights for Formulation Data Navigating the complexities of formulation development requires a strategic approach, especially when prototypes prove not scalable during early development…

Strategies for Addressing Scale-Up Issues in Early Formulation Development In pharmaceutical development, encountering a prototype that is not scalable poses significant risks, particularly during the critical transition from formulation development…

Addressing Late-Stage Excipient Incompatibility in Early Development to Avoid Reformulation Challenges In pharmaceutical manufacturing, identifying excipient incompatibility during the early development stages is crucial for successful formulation development. Late detection…

Addressing Unexplained Dissolution Variability During Tech Transfer Dissolution variability during tech transfer poses significant challenges for pharmaceutical companies, particularly when faced with late-stage reformulation. These variances can stem from numerous…

Addressing Formulation Stability Failures During IND/NDA Filings: A Practical Playbook In the complex world of pharmaceutical development, there are few more challenging situations than a formulation failing to meet stability…

Addressing Missing QbD Elements during IND/NDA Submissions: A Playbook for Pharma Professionals In today’s highly regulated pharmaceutical landscape, the seamless submission of Investigational New Drug (IND) and New Drug Application…

Mitigation Playbook for Bioavailability Risks During Scale-Up Preparation Bioavailability risks during scale-up preparation present significant challenges in the realm of pharmaceutical development. As teams transition from R&D to production, the…

Addressing Scalability Challenges During IND/NDA Filings to Prevent Late-Stage Reformulation As pharmaceutical professionals engaged in formulation and process development, encountering a prototype not scalable during IND/NDA filing stages is a…

Managing Bioavailability Risks Identified During Regulatory Review: A Comprehensive Playbook In the pharmaceutical manufacturing landscape, the identification of bioavailability risks during regulatory review can pose significant challenges for formulation development…

Tackling Scalability Issues in Formulation Development: An Actionable Playbook In the realm of pharmaceutical manufacturing, the transition from prototype to scalable production can often present unforeseen challenges. A failure to…